Syngene reports mixed Q2 and H1 FY26 results amid strategic growth

Syngene International Limited reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company's Q2 FY26 revenue from operations grew 2% year-on-year to INR 9,106 million, and H1 FY26 revenue from operations increased 6% year-on-year to INR 17,851 million. However, Q2 FY26 EBITDA from operations decreased by 18.5% to INR 1,996 million, with a PAT after exceptional items of INR 671 million, a 36.7% decline from Q2 FY25.

Despite the decline in EBITDA and PAT, the company highlighted strategic progress. During Q2 FY26, Syngene secured its first global phase III clinical trial contract from a U.S.-based biotech company and expanded its clinical trials footprint. It is also building a new GMP bioconjugation suite in Bengaluru and progressing with the operationalization of the Bayview biologics manufacturing facility in the U.S.

The company is maintaining its annual guidance for revenue, EBITDA, and PAT margin for the full year, indicating confidence despite the immediate financial shifts.